Close

Thermo Fisher Scientific Opens New Bioprocessing Collaboration Center in St. Louis

Related stories

hubXchange Announces Upcoming Series of Exclusive Roundtable Events in San Diego – February 2025

hubXchange, the premier platform for senior-level knowledge exchange in...

Aragen receives Platinum Medal from EcoVadis for its sustainability initiatives

Hyderabad: Aragen Life Sciences, a globally renowned Contract Research,...

Switzerland’s Basel Region Crowned ‘Europe’s Top Destination to Launch a Drug Device Company’, According to Pharmapack Report

Paris: New research released ahead of Pharmapack Europe – the continent’s largest...

Danish protein analysis to revolutionize the biopharma industry’s impurity control

The requirements for quality assurance of biologics are increasing....

Berry Global Healthcare to Showcase New Packaging Innovations at Pharmapack 2025

Berry Global Healthcare, a leader in innovative packaging solutions,...

Thermo Fisher Scientific Inc., the world leader in serving science, announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri.

The facility is adjacent to the company’s biologics manufacturing facility, which recently doubled production capacity with a $50 million expansion. The combined expertise from Thermo Fisher’s bioproduction and pharma services businesses will accelerate innovation and enhance productivity for biopharma companies, enabling them to meet the growing need for more flexible, scalable biologics development and manufacturing solutions.

“Our St. Louis site is among the world’s largest producers of biologics using single-use technology and the ideal location for this unique collaboration,” said Michael Shafer, senior vice president and president, pharma services, Thermo Fisher Scientific. “These complementary businesses will work together to develop innovative bioprocessing technologies, products and services. This will enhance bioprocess workflows and enable our customers to take their products to market faster and with greater efficiency.”

In 2019, four out of every 10 drugs under development were biologics-based and this growth continues to drive demand for innovation. The BCC will bring together the company’s leadership in GMP biologics manufacturing with its deep expertise in bioprocessing technologies including bioreactors, cell culture media, chromatography and analytical tools, among others. This collaboration will deliver new single-use bioprocessing technologies as well as drive critical process, data management and quality improvements that enable scale-up solutions for biopharma customers.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories